SZSE:002864 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SZSE:002864 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-29), Shaanxi Panlong Pharmaceutical Group's share price is ¥29.00. Shaanxi Panlong Pharmaceutical Group's Owner Earnings per Share (TTM) ended in Mar. 2024 was ¥0.66. It's Price-to-Owner-Earnings for today is 43.94.
The historical rank and industry rank for Shaanxi Panlong Pharmaceutical Group's Price-to-Owner-Earnings or its related term are showing as below:
During the past 11 years, the highest Price-to-Owner-Earnings of Shaanxi Panlong Pharmaceutical Group was 99.19. The lowest was 32.62. And the median was 49.30.
As of today (2024-05-29), Shaanxi Panlong Pharmaceutical Group's share price is ¥29.00. Shaanxi Panlong Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1.19. Therefore, Shaanxi Panlong Pharmaceutical Group's PE Ratio for today is 24.37.
As of today (2024-05-29), Shaanxi Panlong Pharmaceutical Group's share price is ¥29.00. Shaanxi Panlong Pharmaceutical Group's EPS without NRI for the trailing twelve months (TTM) ended in was ¥1.24. Therefore, Shaanxi Panlong Pharmaceutical Group's PE Ratio without NRI for today is 23.46.
During the past 11 years, Shaanxi Panlong Pharmaceutical Group's highest PE Ratio without NRI was 109.30. The lowest was 19.33. And the median was 31.76.
The historical data trend for Shaanxi Panlong Pharmaceutical Group's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shaanxi Panlong Pharmaceutical Group Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Owner-Earnings | Get a 7-Day Free Trial | - | 43.61 | 45.60 | 51.86 | 68.61 |
Shaanxi Panlong Pharmaceutical Group Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Price-to-Owner-Earnings | Get a 7-Day Free Trial | 57.70 | 59.31 | 57.82 | 68.61 | 43.75 |
For the Drug Manufacturers - Specialty & Generic subindustry, Shaanxi Panlong Pharmaceutical Group's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Shaanxi Panlong Pharmaceutical Group's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Shaanxi Panlong Pharmaceutical Group's Price-to-Owner-Earnings falls into.
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Shaanxi Panlong Pharmaceutical Group's Price-to-Owner-Earnings for today is calculated as
Price-to-Owner-Earnings | = | Share Price | / | Owner Earnings per Share (TTM) |
= | 29.00 | / | 0.66 | |
= | 43.94 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shaanxi Panlong Pharmaceutical Group (SZSE:002864) Price-to-Owner-Earnings Explanation
For how to get Owner Earnings per Share (TTM), please click.
Thank you for viewing the detailed overview of Shaanxi Panlong Pharmaceutical Group's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.
Zhang De Zhu | Directors, executives | |
Liu Zhao | Supervisors | |
Jian Bao Liang | Supervisors | |
Zhang Zhi Hong | Directors, executives | |
Zhang Shui Ping | Director | |
Wu Jie | Directors, Directors, and Executives | |
Zhu Feng Ming | Executives | |
Zhu Wen Feng | Director | |
Xie Xiao Feng | Director | |
Xie Xiao Lin | Directors, executives |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.